Drugs / RXI-109
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01780077 | Dec 2012 → Jun 2014 | — | RXi Pharmaceuticals, Corp. | Completed | No outcome recorded |
| Phase 1 | NCT01640912 | Jun 2012 → Apr 2014 | — | RXi Pharmaceuticals, Corp. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02599064 | Nov 2015 → Apr 2018 | age-related macular degeneration, choroidal neovascularization, preretinal fibrosis | RXi Pharmaceuticals, Corp. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02246465 | Jul 2014 → Dec 2017 | reactive cutaneous fibrous lesion | RXi Pharmaceuticals, Corp. | Unknown | No outcome recorded |
| Phase 2 | NCT02079168 | Mar 2014 → Mar 2016 | keloid | RXi Pharmaceuticals, Corp. | Completed | No outcome recorded |
| Phase 2 | NCT02030275 | Nov 2013 → Jun 2016 | reactive cutaneous fibrous lesion | RXi Pharmaceuticals, Corp. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RXI-109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02246465 ↗ |
| Route | Other | “Single intradermal injection of RXI-109 at incision sites” NCT01640912 ↗ |